Castle Biosciences, Inc. (CSTL)
Largest Insider Buys in Sector
CSTL Stock Price History Chart
CSTL Stock Performance
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test …
Insider Activity of Castle Biosciences, Inc.
Over the last 12 months, insiders at Castle Biosciences, Inc. have bought $0 and sold $8.49M worth of Castle Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Castle Biosciences, Inc. have bought $49,058 and sold $95.62M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,800 shares for transaction amount of $69,004 was made by Goldberg Ellen (director) on 2023‑06‑05.
List of Insider Buy and Sell Transactions, Castle Biosciences, Inc.
| 2024-12-17 | Sale | Pres. & Chief Exec. Officer | 9,364 0.0336% | $28.34 | $265,358 | -2.17% | ||
| 2024-12-16 | Sale | Pres. & Chief Exec. Officer | 11,059 0.0398% | $28.83 | $318,864 | -3.35% | ||
| 2024-12-13 | Sale | Pres. & Chief Exec. Officer | 14,764 0.052% | $28.64 | $422,840 | -2.53% | ||
| 2024-12-05 | Sale | Pres. & Chief Exec. Officer | 4,529 0.016% | $31.35 | $141,993 | -9.45% | ||
| 2024-12-03 | Sale | director | 6,442 0.0233% | $30.98 | $199,551 | -4.22% | ||
| 2024-11-15 | Sale | Chief Financial Officer | 6,923 0.0241% | $29.93 | $207,217 | +5.77% | ||
| 2024-11-12 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0169% | $34.15 | $154,665 | -9.34% | ||
| 2024-11-05 | Sale | Chief Commercial Officer | 3,507 0.0132% | $35.56 | $124,709 | 0.00% | ||
| 2024-11-04 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0156% | $32.54 | $147,362 | -9.51% | ||
| 2024-11-01 | Sale | Chief Commercial Officer | 3,100 0.0119% | $35.39 | $109,709 | -7.98% | ||
| 2024-11-01 | Sale | director | 6,442 0.0243% | $34.73 | $223,755 | -7.98% | ||
| 2024-10-14 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0188% | $32.27 | $146,164 | -8.35% | ||
| 2024-10-08 | Sale | Pres. & Chief Exec. Officer | 2,264 0.0088% | $30.27 | $68,529 | +4.33% | ||
| 2024-10-07 | Sale | director | 6,442 0.0244% | $29.44 | $189,672 | +5.86% | ||
| 2024-10-04 | Sale | Pres. & Chief Exec. Officer | 2,265 0.0084% | $28.73 | $65,083 | +6.27% | ||
| 2024-09-16 | Sale | Pres. & Chief Exec. Officer | 4,529 0.0163% | $30.97 | $140,272 | -1.29% | ||
| 2024-09-11 | Sale | Pres. & Chief Exec. Officer | 2,296 0.0086% | $30.32 | $69,615 | 0.00% | ||
| 2024-09-09 | Sale | Pres. & Chief Exec. Officer | 2,286 0.0083% | $29.46 | $67,339 | +4.42% | ||
| 2024-09-05 | Sale | director | 6,442 0.0229% | $29.02 | $186,973 | +3.63% | ||
| 2024-09-04 | Sale | Pres. & Chief Exec. Officer | 700 0.0026% | $30.02 | $21,017 | +5.60% |
Insider Historical Profitability
| MGC Venture Partners 2013 GP, LLC | 10 percent owner | 1464020 5.2273% | $27.53 | 1 | 3 | +21.26% |
| Sofinnova HealthQuest Partners, L.P. | 1433577 5.1186% | $27.53 | 1 | 8 | +21.26% | |
| KABAKOFF DAVID S | director | 503577 1.798% | $27.53 | 1 | 29 | +21.26% |
| Cook Joseph C. III | director | 112178 0.4005% | $27.53 | 1 | 46 | +21.26% |
| Aspinall Mara G. | director | 30848 0.1101% | $27.53 | 1 | 4 | +21.26% |
Institutional Investor Ownership
| BlackRock | $57.49M | 9.4 | 2.6M | +13.69% | +$6.92M | <0.01 | |
| Wasatch Advisors | $56.51M | 9.24 | 2.55M | -1.54% | -$882,965.45 | 0.3 | |
| Granahan Investment Management | $36.04M | 5.89 | 1.63M | -24.89% | -$11.94M | 1.27 | |
| The Vanguard Group | $33.1M | 5.41 | 1.49M | +2.24% | +$724,194.24 | <0.01 | |
| Bellevue Group | $27.02M | 4.42 | 1.22M | -1% | -$272,289.95 | 0.41 |